Nuvation Bio Inc. (NUVB) and Eisai Get EMA Validation for Taletrectinib [Yahoo! Finance]
Nuvation Bio Inc. Class A (NUVB)
Company Research
Source: Yahoo! Finance
announced that the European Medicines Agency (EMA) validated the Marketing Authorisation Application (MAA) for Taletrectinib, which is marketed as IBTROZI in the US and Japan. ?Taletrectinib targets advanced ROS1-positive non-small cell lung cancer. Management noted that they expect a standard review timeline. This builds on the earlier January 2026 exclusive licensing deal between Eisai and Nuvation Bio for Europe and select regions outside the US, China, and Japan. ?Management noted that Europe sees around 400,000 annual lung cancer diagnoses, out of which non-small cell lung cancer comprises 80% of the cases and more than 2% advanced ROS1-positive cases. This translates to roughly 6,400 patients a year. Taletrectinib is a highly selective oral ROS1 inhibitor with a strong efficacy and safety profile, positioning it as a potential standard-of-care. ?Nuvation Bio Inc. (NYSE:NUVB) is a biopharmaceutical company developing new treatments for difficult-to-treat cancers. The compan
Show less
Read more
Impact Snapshot
Event Time:
NUVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVB alerts
High impacting Nuvation Bio Inc. Class A news events
Weekly update
A roundup of the hottest topics
NUVB
News
- Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026 [TheStreet.com]TheStreet.com
- Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026PR Newswire
- How Much Can Nuvation Bio (NUVB) Make From Ibtrozi Sales? [Yahoo! Finance]Yahoo! Finance
- Nuvation Bio's Ibtrozi Gains Frontline Momentum Ahead of Key Q1 Print, Wedbush Says [Yahoo! Finance]Yahoo! Finance
- Nuvation Bio (NUVB) had its "outperform" rating reaffirmed by Wedbush. They now have a $11.00 price target on the stock.MarketBeat
NUVB
Earnings
- 3/2/26 - In-Line
NUVB
Sec Filings
- 4/21/26 - Form DEFA14A
- 4/17/26 - Form 144
- 4/17/26 - Form 144
- NUVB's page on the SEC website